Condition: Uveal Melanoma · Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting. Tebentafusp is the first agent proven to improve overall survival in patients with metastatic uveal melanoma in a randomized trial. Based on the results in the advanced setting, it is hypothesized that treatment with tebentafusp may reduce the risk of development of disease recurrence.
This description comes directly from the study's public registry record.
EORTC HQ · +32 2 774 16 11 · eortc@eortc.org
Always discuss trial participation with your own doctor first.
| Northwell Health -Center for Advanced Medicine | Lake Success, New York, United States | Recruiting |
| Cliniques Universitaires Saint-Luc | Brussels, Belgium | Recruiting |
| Centre Antoine Lacassagne | Nice, France | Recruiting |
| Institut Curie - Hôpital de Paris | Paris, France | Recruiting |
| Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin | Berlin, Germany | Recruiting |
| Universitaets Krankenhaus Eppendorf - Universitaetsklinikum Hamburg-Eppendorf KE - University Cancer Center | Hamburg, Germany | Recruiting |
| Universitaetsklinikum Heidelberg - Frauenklinik / Hautklinik | Heidelberg, Germany | Recruiting |
| Leiden University Medical Centre | Leiden, Netherlands | Recruiting |
| Erasmus MC | Rotterdam, Netherlands | Recruiting |
| Maria Sklodowska-Curie Memorial Cancer Centre - Maria Sklodowska-Curie National Research Institute of Oncology | Warsaw, Poland | Recruiting |
| Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia) | L'Hospitalet de Llobregat, Spain | Recruiting |
| Hospital Clinico Universitario De Valladolid | Valladolid, Spain | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06246149